Cerus/$CERS
Cerus shares fall as investors focus on the red-cell CE-mark delay to late 2027 and the FDA’s request for additional INT200 data, alongside reaffirmed rather than raised full-year revenue guidance.
12 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
- Ticker
- $CERS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 268
- Headquarters
- Concord, United States
- Website
- www.cerus.com
Cerus Metrics
BasicAdvanced
$430M
-
-$0.04
1.85
-
Price and volume
Market cap
$430M
Beta
1.85
52-week high
$3.47
52-week low
$1.38
Average daily volume
2M
Financial strength
Current ratio
1.957
Quick ratio
1.096
Long term debt to equity
0.565
Total debt to equity
0.982
Interest coverage (TTM)
-0.36%
Profitability
EBITDA (TTM)
-0.748
Gross margin (TTM)
51.83%
Net profit margin (TTM)
-3.23%
Operating margin (TTM)
-1.09%
Effective tax rate (TTM)
-5.28%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-0.74%
Return on equity (TTM)
-10.67%
Valuation
Price to revenue (TTM)
1.853
Price to book
5.68
Price to tangible book (TTM)
5.78
Price to free cash flow (TTM)
850.299
Free cash flow yield (TTM)
0.12%
Free cash flow per share (TTM)
0.003
Growth
Revenue change (TTM)
13.74%
Earnings per share change (TTM)
-56.08%
3-year revenue growth (CAGR)
13.82%
10-year revenue growth (CAGR)
19.96%
3-year earnings per share growth (CAGR)
-48.87%
10-year earnings per share growth (CAGR)
-24.76%
What the Analysts think about Cerus
Analyst ratings (Buy, Hold, Sell) for Cerus stock.
Analyst projections of the future price of Cerus stock.
Bulls say / Bears say
Third-quarter product revenue rose 10% year on year, and Cerus maintained its full-year outlook for 11%–12% growth. That points to continued demand across its established product business. (Business Wire)
INTERCEPT Fibrinogen Complex volumes grew about 80% year on year in the third quarter, with sales rising to $5.6 million from $3.9 million. Faster adoption of this newer product could add a further growth driver. (Business Wire)
Cerus said its Phase 3 REDeS trial met its main efficacy goal: red blood cells treated with INTERCEPT were non-inferior to conventional units on adjusted haemoglobin increment. This is an important clinical milestone for a potential future product, although approval is still required. (Business Wire)
Cerus now expects European clearance for its red-cell system in late 2027, later than previously planned. It intends to begin with a limited release at selected centres, delaying the prospect of broader sales. (The Motley Fool)
The FDA has raised questions on the INT200 platelet-device submission and Cerus says it needs to gather additional data. The company has not yet given a clear approval timeline, leaving uncertainty around this product rollout. (The Motley Fool)
Cerus recorded a $5.2 million net loss over the first nine months of 2026, while product gross margin eased to 52.4% from 53.4% a year earlier. This shows that revenue growth has not yet translated into sustained profitability. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Cerus Financial Performance
Revenues and expenses
Cerus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cerus News
AllArticlesVideos
Funds containing Cerus
Fund name | Fund size | $CERS weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 0.91% |
ARK Genomic Revolution£ARCG | $123M | 0.91% |
ARK Innovation£ARCK | $325M | 0.36% |
ARK Innovation€ARXK | $325M | 0.36% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.